

National Institute for Health & Clinical Excellence

Food Allergy in Children

Fourth Guideline Development Group (GDG) meeting

Monday 5th & Tuesday 6th July 2010

Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

GROUP MEMBERSHIP

In Attendance	
GDG Members	
Peter Barry (Chair) (PB)	Sue Clarke
Trevor Brown	Adam Fox
Mandy East	Amanda Roberts
Peter MacFarlane	Paula Beattie
Lisa Waddell	Joanne Walsh
Carina Venter	
NICE Staff	
Kathryn Chamberlain (KC)	Alfred Sackeyfio (AS)
Abi Senthinathan (ASe)	Claire Turner (CT)
Prashanth Kandaswamy (PK)	Michael Heath (MH)
Apologies:	

MINUTES OF THE MEETING

Monday 5th July 2010

1.1 Agenda item 1:

• **Objectives and introductions**

Carina Venter attended the meeting for the first time, so the whole group introduced themselves.

The aim of the meeting is to look at the evidence around alternative tests, the review of reviews and the JAMA paper.

The next day the GDG will revisit and agree the evidence statements, recommendations, and discuss the research recommendations.

• **DOI**

The group discussed the DOI and the groups they work with and events they have attended. All DOI's will be listed on the NICE website following publication of the guideline.

• **Minutes of the last meeting**

The notes from the last meeting were agreed.

1.2 Agenda items 2: Alternative tests – Evidence presented & discussion

AS presented an overview of the evidence on alternative tests, including the inclusion/exclusion criteria. The GDG then agreed the evidence statements. AS

confirmed that the search terms used included both alternative and complementary. IgG was searched as alternative and complementary, plus as a term in itself.

The GDG then continued to draft recommendations.

1.3 Agenda items 3 & 4: Final presentation of evidence – Questions 1 & 2

ASe presented the review of reviews that had been requested, to add onto question 1. Additional evidence statements were agreed as a result of the review.

The GDG discussed and agreed the list of signs and symptoms for recommendation 1, non IgE mediated symptoms.

1.4 Agenda item 5: Additional systematic review

ASe gave an overview of the JAMA paper.

The evidence statements had been updated to include the additional systematic reviews. The GDG agreed the updated evidence statement.

1.5 Agenda item 1 (from Day 2): Health Economics

The HE was brought forward from day 2.

PK reminded the GDG what had been done regarding the HE. He explained that he had not done a new analysis on the non IgE mediated food allergies as he had used an already published model.

For IgE mediated food allergy there were no published HE analyses. The cost data came from the manufacturer. Both tests came out as being cost effective. If the GDG want the full analysis, PK is happy to forward it to them.

Tuesday 6th July 2010

1.1 Agenda item 2 & 3: Full guideline

The GDG spent the day discussing the full guideline. This included discussing and agreeing the evidence statements, the evidence to recommendations and all the recommendations.

They also discussed terms that should be added to the glossary.

1.2 Agenda item 4: Research recommendations

It was agreed that KC would email the GDG to request their suggestions for research recommendations.

1.3 Agenda item 5: AOB

The next meeting will be post consultation, and will be to discuss the stakeholder comments. It will be held in NICE London office on 28th September.

PB closed the meeting